IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gregory Rasp who wrote (1455)	2/4/1998 4:20:00 AM
From: Maurice Winn	Read Replies (1) of 1762

Greg, You said: "Lastly, I agree that in a 2cm node the use of Radiation (XRT) is probably not indicated in most cases." Well, that isn't what they think for Tarken. They say radiation is necessary [with some dissenting opinion] to back up 3xCHOP. Based on a recent study called "SWOG" which was reported in abstract by the American Society of Clinical Oncologists [ASCO] which said that 3 doses of CHOP plus involved field radiation is as good as 6 doses of CHOP alone. We have not been able to get hold of that study. Do you know the one I mean? Can you give me a web reference? We couldn't get into the web site as it is accessible only to oncologists. Actually, best of all would be a copy of the abstract. Or full article/study if available. Please drop it in here for the IDPH crowd to see what the competition are doing, or email me, or drop it here: Subject 3190 Thanks if you are able to help. Maurice PS: I guess that fairly soon, standard treatment will be 3xCHOP, 40 Gray of short wave emr, Rituxan, I131, TNT and some vasopermeation. As cancer cell targeting accuracy goes up with newer techniques, CHOP and 40 Gray will go down.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next